WaveMan
WaveMan · Company
RPRX · Royalty Pharma Plc
> Search tickers & screens ⌘K
LIVE
← All companies

RPRX Royalty Pharma (RPRX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001802768
Quote by TradingView
Form 144 · 7
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
397
13F, latest reported quarter

What the filings say about RPRX

Insiders, 180 days
-$34.6M net sold
4 sellers · 21% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$32.1M
7 notices

Royalty Pharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Royalty Pharma plc insiders sold a net $34.6M of stock across 209 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Urist Marshall
EVP, Research & Investments
SELL
2026-10-05 SEC
4,126
$235.6K
+14.7%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Sep 28, 2026.
  • 1 other insider sold within 30 days.
  • 397 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Research & Investments Urist Marshall sold about $235.6K of RPRX under a 10b5-1 plan on Oct 5, 2026; 1 other insider sold within 30 days and 397 funds added in the latest 13F quarter.
Urist Marshall
EVP, Research & Investments
SELL
2026-09-30 SECtraded 2026-09-28
4,126
$238.8K
+12.4%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Jul 1, 2026.
  • The trade is 100.0% of the 4,126 shares held after it.
  • 1 other insider sold within 30 days.
  • 397 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Research & Investments Urist Marshall sold about $238.8K of RPRX under a 10b5-1 plan on Sep 28, 2026; 1 other insider sold within 30 days and 397 funds added in the latest 13F quarter.
Hite Christopher
EVP & Chairman, Partnering
SELL
2026-09-24 SECtraded 2026-09-22
96,073
$5.6M
+11.3%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Aug 18, 2026.
  • The trade is 35.0% of the 274,328 shares held after it.
  • 1 other insider sold within 30 days.
  • 397 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chairman, Partnering Hite Christopher sold about $5.6M of RPRX under a 10b5-1 plan on Sep 22, 2026; 1 other insider sold within 30 days and 397 funds added in the latest 13F quarter.
Hite Christopher
EVP & Chairman, Partnering
SELL
2026-09-24 SECtraded 2026-09-22
3,927
$231.4K
+11.3%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Aug 18, 2026.
  • The trade is 1.5% of the 270,401 shares held after it.
  • 1 other insider sold within 30 days.
  • 397 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chairman, Partnering Hite Christopher sold about $231.4K of RPRX under a 10b5-1 plan on Sep 22, 2026; 1 other insider sold within 30 days and 397 funds added in the latest 13F quarter.
Hite Christopher
EVP & Chairman, Partnering
SELL
2026-08-19 SECtraded 2026-08-18
100,000
$6.0M
+6.9%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 30, 2026.
  • The trade is 27.0% of the 370,401 shares held after it.
  • 1 other insider sold within 30 days.
  • 397 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chairman, Partnering Hite Christopher sold about $6.0M of RPRX on Aug 18, 2026; 1 other insider sold within 30 days and 397 funds added in the latest 13F quarter.
209 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 204 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$34.6M over 180 days
-$13.0M over 90 days
below 92% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
397 funds bought in last quarter
more than 96% of Pharma & Biotech
Revenue
+5.1% year over year
more than 53% of Pharma & Biotech
Margin
32.4% net margin
more than 92% of Pharma & Biotech
Buybacks
$94.7M repurchased, FY to 2026-06-30
more than 68% of Pharma & Biotech
Short interest
3.1% of the float short (float per yahoo 2026-10-27) · 4.3 days to cover · settled 2026-10-15
below 57% of Pharma & Biotech
What changed in the last 30 days
Oct 5EVP, Research & Investments Urist Marshall sold $474.4K under a 10b5-1 plan (2 trades, Sep 28 to Oct 5)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 5Officer Urist Marshall filed to sell $235.6K by Oct 5 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch RPRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+79.1%12M
-1%+26%+52%+79%2025-102025-122026-022026-042026-062026-082026-10 2026-06-23 · Hite Christopher sold $6.4M2026-08-18 · Hite Christopher sold $6.0M2026-09-22 · Hite Christopher sold $5.6M2026-06-30 · Hite Christopher sold $5.5M2026-02-03 · Coyne Terrance P. sold $4.7M2025-12-03 · Lloyd George W. sold $4.4M2026-02-02 · Coyne Terrance P. sold $4.3M2026-05-26 · Coyne Terrance P. sold $3.5M2025-12-17 · Lloyd George W. sold $3.1M2025-12-01 · Coyne Terrance P. sold $2.6M2026-01-20 · Coyne Terrance P. sold $2.6M2025-11-17 · Coyne Terrance P. sold $2.6M2026-01-02 · Coyne Terrance P. sold $2.5M2025-12-15 · Coyne Terrance P. sold $2.5M2025-11-24 · Coyne Terrance P. sold $2.1M2025-11-19 · Lloyd George W. sold $1.8M2025-11-19 · Lloyd George W. sold $1.8M2026-06-23 · Hite Christopher sold $1.8M2026-06-30 · Hite Christopher sold $1.7M2026-04-28 · Coyne Terrance P. sold $1.6M2026-04-01 · Coyne Terrance P. sold $1.6M2026-03-23 · Coyne Terrance P. sold $1.5M2026-02-23 · Coyne Terrance P. sold $1.5M2025-12-18 · Lloyd George W. sold $1.2M2026-03-02 · Coyne Terrance P. sold $1.0M2025-11-19 · Lloyd George W. sold $977.3K2025-12-01 · Urist Marshall sold $931.7K2025-12-05 · Urist Marshall sold $913.5K2026-02-04 · Coyne Terrance P. sold $825.8K2026-01-30 · Urist Marshall sold $821.8K2026-01-09 · Urist Marshall sold $815.6K2026-01-23 · Urist Marshall sold $805.2K2026-01-16 · Urist Marshall sold $790.4K2025-12-26 · Urist Marshall sold $786.4K2026-01-02 · Urist Marshall sold $769.6K2025-12-19 · Urist Marshall sold $767.6K2025-12-16 · Urist Marshall sold $766.4K2025-12-01 · Urist Marshall sold $727.9K2026-05-14 · Urist Marshall sold $726.1K2026-05-20 · Urist Marshall sold $721.8K2025-12-05 · Urist Marshall sold $714.2K2026-08-13 · Coyne Terrance P. sold $540.8K2026-10-05 · Urist Marshall filed to sell $235.6K2026-09-28 · Urist Marshall filed to sell $238.8K2026-09-22 · SCH Investment Partners LLC filed to sell $5.8M2026-08-18 · SCH Investment Partners LLC filed to sell $6.0M2026-08-13 · Terrance Coyne filed to sell $644.3K2026-08-12 · Errol B. De Souza filed to sell $7.2M2026-08-12 · Errol B. De Souza filed to sell $11.9M2026-07-01 · SCH Investment Partners LLC filed to sell $5.7M2026-07-01 · Urist Marshall filed to sell $508.5K2026-06-24 · Urist Marshall filed to sell $502.1K2026-06-23 · Christopher Hite filed to sell $1.7M2026-06-23 · SCH Investment Partners LLC filed to sell $8.2M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RPRX: institutional holders (13F)

13F holdings, latest reported quarter
MORGAN STANLEY
42,931,597 sh
$2.4B
Capital International Investors
35,273,770 sh
$2.0B
BlackRock, Inc.
27,832,977 sh
$1.6B
FMR LLC
24,513,814 sh
$1.4B
STATE STREET CORP
12,338,229 sh
$691.8M

Congress trades in RPRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RPRX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Urist Marshall
Filed 2026-10-05
$235.6K
Urist Marshall
Filed 2026-09-28
$238.8K
SCH Investment Partners LLC
Filed 2026-09-22
$5.8M
SCH Investment Partners LLC
Filed 2026-08-18
$6.0M
Terrance Coyne
Filed 2026-08-13
$644.3K

RPRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Biotechnology & Genome ETF
$13.9M position · as of 2026-07-31
4.9%
iShares U.S. Pharmaceuticals ETF
$49.3M position · as of 2026-06-30
4.3%
Eventide Large Cap Focus Fund
$8.3M position · as of 2026-06-30
4.1%
Eventide High Dividend ETF
$9.4M position · as of 2026-07-31
3.7%
Heartland Value Plus Fund
$10.7M position · as of 2026-06-30
3.2%
AVIP Fidelity Institutional AM Equity Growth Portfolio
$7.7M position · as of 2026-06-30
3.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $34.6M sold by insiders over 180 days, 397 funds added last quarter, $32.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RPRX financials

Revenue growth
+5.1%
XBRL, annual
Net margin
32.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.5B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+32.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.92x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.33x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+8.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+4.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+8.5%
operating income after a 0.0% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+8.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
34.45x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$33.3B
market value at close 2026-10-26 on 2020-11-10 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing EPS growth -18%, PEG needs growth
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$2.4B$2.3B$2.4B$2.2B
Operating income$1.6B$1.3B$1.5B$307.1M
Net income$770.9M$859.0M$1.1B$42.8M
EPS (diluted)1.781.912.530.10
Operating cash flow$2.5B$2.8B$3.0B$2.1B
Cash$618.7M$929.0M$477.0M$1.7B
Long-term debt$8.6B$6.6B$6.1B$6.1B
Buybacks$1.2B$229.7M$304.8M$0
SEC XBRL, fiscal years, as known on 2026-10-28

RPRX Stock Sonar score 6/7 axes

Find similar shapesCompare

RPRX ranks highest on institutional and government (96th percentile) and profitability (71st), and lowest on insider conviction (4th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
71
Inputs
  • Return on equity+8.5% · 84 pct, sector of 545
  • Return on assets+4.3% · 84 pct, sector of 691
  • Return on invested capital+8.5% · 27 pct, sector of 45
  • Return on capital employed+8.3% · 89 pct, sector of 576
Financial health
53
Inputs
  • Debt to equity0.92x · 21 pct, sector of 352
  • Cash flow to debt0.33x · 86 pct, sector of 371
Growth
53
Inputs
  • Revenue growth, YoY+5.1% · 53 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
4
Inputs
  • Net Form 4 buying (codes P and S), 180d-$28.2M · 7 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
96
Inputs
  • Funds adding, latest quarter397 · 96 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
55
Inputs
  • Short interest, % of float+3.1% · 66 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+11.9% · 43 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RPRX filings, in plain words

Are Royalty Pharma insiders buying or selling RPRX?

In the 180 days to 2026-10-28, Royalty Pharma insiders were net sellers, a net $34.6M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of RPRX?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $32.1M of stock; the latest, by Urist Marshall, was filed 2026-10-05.

Read the full summary

In the 180 days to 2026-10-28, Royalty Pharma insiders were net sellers of RPRX, a net $34.6M across purchases and sales reported on Form 4 by 4 sellers. 21% of the 19 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $32.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies